HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dalakas, M. C. Search for Related Content PubMed PubMed Citation Articles by Dalakas, M. C.

Controlled Studies with High-Dose Intravenous Immunoglobulin in the Treatment of Dermatomyositis, Inclusion Body Myositis, and Polymyositis

Front the Neuromuscular Diseases Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health Bethesda, MD.

Address correspondence and reprint requests to Dr. Marinos C. Dalakas, Neuromuscular Diseases Section, NINDS, National Institutes of Health, Building 10, Room 4N248, 10 Center Drive MSC 1382, Bethesda, MD 20892-1382.

Abstract.

There are three major subsets of the inflammatory myopathies: polymyositis (PM), dermatomyositis (DM), and inclusion-body myositis (IBM). High-dose intravenous immunoglobulin (IVIg) has been tried in controlled clinical trials in patients with DM and IBM but not with PM. In patients with DM that is resistant or partially responsive to conventional therapies. IVIg was very effective. The treated patients experienced dramatic improvement not only in muscle strength but also of their skin rash. Repeated muscle biopsies with quantitative histologic studies showed the IVIg-treated patients had a statistically significant improvement of the muscle cytoarchitecture, with resolution of the aberrant immunopathologic parameters. In two controlled clinical trials conducted in IBM patients, IVIg showed marginal improvements in muscle strength which were nonsignificant. However, a few IBM patients had a definite clinical improvement with increased activities of daily living, but when analyzed within the entire IVIg-treated group, their total gains in muscle strength did not reach statistical significance compared to the placebo-treated group. Of interest is that certain muscle groups in the IVIg-treated patients, such as the muscles of swallowing, showed significant improvement compared to those of the placebo-treated patients, implying mild regional effects. In PM, uncontrolled trials have shown improvements in muscle strength, but the controlled clinical trial is still ongoing.

This article has been cited by other articles:

				S. A Greenberg How citation distortions create unfounded authority: analysis of a citation network BMJ, July 23, 2009; 339(jul20_3): b2680 - b2680. [Abstract] [Full Text] [PDF]

				B Ranque-Francois, T Maisonobe, E Dion, J-C Piette, M-P Chauveheid, Z Amoura, and T Papo Familial inflammatory inclusion body myositis Ann Rheum Dis, April 1, 2005; 64(4): 634 - 637. [Abstract] [Full Text] [PDF]

				H. G. Roed, A. Langkilde, F. Sellebjerg, M. Lauritzen, P. Bang, A. Morup, and J. L. Frederiksen A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis Neurology, March 8, 2005; 64(5): 804 - 810. [Abstract] [Full Text] [PDF]

				H. U. Lutz, P. Stammler, V. Bianchi, R. M. Trueb, T. Hunziker, R. Burger, E. Jelezarova, and P. J. Spath Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level Blood, January 15, 2004; 103(2): 465 - 472. [Abstract] [Full Text] [PDF]

				S. B. Rutkove, R. A. Parker, R. A. Nardin, C. E. Connolly, K. J. Felice, and E. M. Raynor A pilot randomized trial of oxandrolone in inclusion body myositis Neurology, April 9, 2002; 58(7): 1081 - 1087. [Abstract] [Full Text] [PDF]